Blood transfusion

Global Blood Transfusion Devices Market Analysis 2020-2025 - The Pathogen Reduction System is Expected to Witness Healthy Growth - ResearchAndMarkets.com

Friday, May 29, 2020 - 11:58am

The "Blood Transfusion Devices Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Blood Transfusion Devices Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.
  • The rise in the number of blood disorders, such as anemia, leukopenia, erythrocytosis, leukocytosis, and thrombocytosis is also boosting the blood transfusion market.
  • The pathogen reduction system segment of the blood transfusion market is believed to witness a healthy growrh over the forecast period.
  • Companies like Immucor Inc., Becton Dickinson, B. Braun, Terumo Corporation, and Grifols SA., hold a significant share in the blood transfusion market.

Desert Financial Arena Community Blood Drive on May 31 Aims for 350-Plus Donors

Friday, May 22, 2020 - 11:51pm
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20200522005465/en/
    Your donation of blood helps kids like 4-year-old Adelyn, who just had her 66th blood transfusion.
  • (Photo: Business Wire)
    Healthy, eligible donors are invited to the Desert Financial Arena Community Blood Drive Sunday, May 31, from 8:00 a.m. to 2:00 p.m. at Desert Financial Arena on the Arizona State University campus in Tempe.
  • The first 350 donors will receive an ASU/Desert Financial T-shirt in appreciation for giving blood at this crucial time.
  • Vitalant , Arizonas largest nonprofit community blood provider has partnered to host the blood drive.

The Blood Connection Provides Free COVID-19 Antibody Testing to All Blood Donors

Monday, May 11, 2020 - 2:00pm

The Blood Connection (TBC), a local non-profit, community blood center, is offering COVID-19 antibody testing to all donors at no cost, beginning Monday, May 11.

Key Points: 
  • The Blood Connection (TBC), a local non-profit, community blood center, is offering COVID-19 antibody testing to all donors at no cost, beginning Monday, May 11.
  • TBC will be offering this testing to donors at all donation centers and blood mobiles.
  • This testing is only available to blood donors and a complete donation must be made in order to be tested.
  • If you would like to have the COVID-19 Antibody Test, please make an appointment to donate blood with The Blood Connection, find a drive near you by visiting thebloodconnection.org/donate-blood .

PSI Wins $23M Recompete to Provide EBMS Transfusion Sustainment Services to Support DHA

Thursday, May 7, 2020 - 3:00pm

The PSI Team has proudly partnered with DHA to develop and sustain all aspects of the EBMS Transfusion Sustainment program system since its inception in March 2011.

Key Points: 
  • The PSI Team has proudly partnered with DHA to develop and sustain all aspects of the EBMS Transfusion Sustainment program system since its inception in March 2011.
  • PSI successfully implemented, migrated, and integrated the blood transfusion services of 56 Military Treatment Facilities (MTFs) to a web-based application, improving application performance by 76%.
  • The Firm Fixed Price contract includes four one-year options for a total award amount of $23.2 million.
  • For more information on PSI, visit www.plan-sys.com and connect with us on LinkedIn and Facebook .

Cerus Corporation Announces FDA Approval for INTERCEPT Blood System for Plasma with Alternate Plastic Disposable Kits

Monday, May 4, 2020 - 1:30pm

Cerus Corporation (Nasdaq:CERS) announced today FDA regulatory approval for manufacture of INTERCEPT plasma with a new, alternative plastic disposable kit.

Key Points: 
  • Cerus Corporation (Nasdaq:CERS) announced today FDA regulatory approval for manufacture of INTERCEPT plasma with a new, alternative plastic disposable kit.
  • The use of the INTERCEPT Blood System for plasma is a natural extension for our U.S. customers who have already adopted INTERCEPT platelets as the standard of care, continued Greenman.
  • Cerus develops and markets the INTERCEPT Blood System and remains the only company in the blood transfusion space to earn both CE Mark and FDA approval for pathogen reduction of both platelet and plasma components.
  • INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

Reblozyl (luspatercept) Receives Positive CHMP Opinion for the Treatment of Adults with Anemia in Beta Thalassemia and Myelodysplastic Syndromes

Thursday, April 30, 2020 - 9:16pm

If approved, Reblozyl would be the first erythroid maturation agent approved in the EU, representing a new class of therapy for eligible patients.

Key Points: 
  • If approved, Reblozyl would be the first erythroid maturation agent approved in the EU, representing a new class of therapy for eligible patients.
  • This decision by the CHMP is an important step towards making this first-in-class therapy an option for eligible patients with anemia due to beta thalassemia or myelodysplastic syndromes, said Diane McDowell, M.D., vice president, Hematology Global Medical Affairs, Bristol Myers Squibb.
  • People with MDS who develop anemia often require regular blood transfusions to increase the number of healthy red blood cells in circulation.
  • Across the United States, Germany, France, Italy, Spain and the United Kingdom, there are approximately 17,000 patients with beta thalassemia.

Global Blood-Grouping Reagents Market 2020-2024 | Evolving Opportunities with Bio-Rad Laboratories Inc. and DIAGAST | Technavio

Wednesday, April 29, 2020 - 12:15am

The global blood-grouping reagents market is expected to grow by USD 443.28 million as per Technavio.

Key Points: 
  • The global blood-grouping reagents market is expected to grow by USD 443.28 million as per Technavio.
  • The market is driven by the growing demand for blood transfusions and blood group typing.
  • In addition, the increasing penetration of healthcare facilities is anticipated to boost the growth of the blood-grouping reagents market.
  • Major Five Blood-Grouping Reagents Companies:
    Bio-Rad Laboratories Inc. operates its business in the Life science and Clinical diagnostics segments.

Eurofins Technologies’ Range of Testing Kits for Serology-based Antibody Detection by ELISA in Patients Exposed to COVID-19 now Available to Order Online by Government Approved Clinical Laboratories Globally

Tuesday, April 21, 2020 - 5:39pm

Those specialized diagnostic technologies companies are well-established providers of testing solutions with a strong focus on scientific excellence in infectious diseases testing and immunology.

Key Points: 
  • Those specialized diagnostic technologies companies are well-established providers of testing solutions with a strong focus on scientific excellence in infectious diseases testing and immunology.
  • Serology can be used to complement the PCR swab testing that detects the virus to help diagnose acute infections status and its evolution.
  • It could help identify donors of plasma from recovered patients that can be transfused into COVID-19 patients as a potential treatment.
  • Online sales to government approved clinical laboratories are open from today and orders can be placed using the following links:

University Hospital Basel, Switzerland Transfuses First Two COVID-19 Patients With INTERCEPT Treated Coronavirus Convalescent Plasma

Thursday, April 2, 2020 - 1:30pm

Cerus Corporation (Nasdaq: CERS) announced today that the University Hospital Basel transfused the first two COVID-19 patients with INTERCEPT treated coronavirus convalescent plasma (CCP).

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) announced today that the University Hospital Basel transfused the first two COVID-19 patients with INTERCEPT treated coronavirus convalescent plasma (CCP).
  • Plasma collected from individuals who have recovered from coronavirus disease contains antibodies against the virus that may help fight the infection.
  • Based on WHO data, plasma collected from recovered COVID-19 patients contains antibodies that neutralize SARS-CoV-2 infectivity and may improve a patients ability to fight COVID-19.
  • Convalescent plasma has been cited as a potential therapy for viral infection dating back to the 1918 Spanish influenza A (H1N1) pandemic.

Cerus Corporation Announces the Inclusion of Pathogen Reduction Technology in the ISBT Working Party Recommendations for the Preparation of COVID-19 Convalescent Plasma

Thursday, April 2, 2020 - 1:30pm

Cerus Corporation (Nasdaq: CERS) announced today that the International Society of Blood Transfusion (ISBT) Working Party on Global Blood Safety issued a new document titled Points to consider in the preparation and transfusion of COVID-19 convalescent plasma.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) announced today that the International Society of Blood Transfusion (ISBT) Working Party on Global Blood Safety issued a new document titled Points to consider in the preparation and transfusion of COVID-19 convalescent plasma.
  • Convalescent plasma has emerged as a promising potential therapeutic to treat acutely ill COVID-19 patients, said Dr. Laurence Corash, Cerus chief scientific officer.
  • These just issued recommendations by the ISBT Working Party on Global Blood Safety provide a framework for institutions involved in collecting, manufacturing, and transfusing COVID-19 convalescent plasma.
  • Convalescent plasma has been cited as a potential therapy for viral infection dating back to the 1918 Spanish influenza A (H1N1) pandemic.